Central Nervous System News and Research

RSS

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

UCI study provides blueprint for enhanced treatment of inflammatory diseases

By discovering how adult neural stem cells navigate to injury sites in the central nervous system, UC Irvine researchers have helped solve a puzzle in the creation of stem cell-based treatments: How do these cells know where to go? Tom Lane and Kevin Carbajal of the Sue and Bill Gross Stem Cell Research Center found the answer with the body's immune system.

2 Jun 2010

Mannitol improves effectiveness of HUCBs in neonatal rat models of cerebral palsy

The sugar-alcohol compound mannitol improved the therapeutic effectiveness of human umbilical cord blood cells injected into neonatal rat models of cerebral palsy, reports a new international study led by the University of South Florida. The mannitol opened the blood-brain barrier by temporarily shrinking the tight endothelial cells that make up the barrier.

2 Jun 2010

Chakra Biotech Sdn Bhd announces name change to Cerca Insights Sdn Bhd

Chakra Biotech Sdn Bhd today announced its name change to Cerca Insights Sdn Bhd. The name change follows the recent completion of a Series B investment round with Malaysian Life Sciences Capital Fund Ltd and the Malaysian Technology Development Corporation Sdn Bhd.

31 May 2010

Adenosine plays major role in parlaying effects of acupuncture

Scientists have taken another important step toward understanding just how sticking needles into the body can ease pain.

31 May 2010

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

UCSF scientists discover new stem cell in developing human brain

UCSF scientists have discovered a new stem cell in the developing human brain. The cell produces nerve cells that help form the neocortex - the site of higher cognitive function -- and likely accounts for the dramatic expansion of the region in the lineages that lead to man, the researchers say.

26 May 2010

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Trigemina, Inc., a Mountain View based privately-held biopharmaceutical company, reports positive results from a time-based interim analysis of its Phase IIa clinical trial in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston. The study compares intranasal oxytocin with placebo in patients suffering from CDH.

26 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol

Bayer HealthCare Pharmaceuticals, Inc. today announced presentation of data in a poster titled "Results from a multicenter, open-label Phase 3 study to determine the safety and efficacy of gadobutrol, a macrocyclic 1.0 molar GBCA in patients referred for contrast-enhanced MRI of the central nervous system (CNS)" at the 48th Annual Meeting of the American Society of Neuroradiology (ASNR) in Boston, MA.

24 May 2010

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co-led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

20 May 2010

AANS/CNS issue statement on Congress hearing of impact of concussions on high school athletes

On Thursday, May 20, 2010, the U.S. House of Representatives Committee on Education and Labor held a hearing to learn more about the impact of concussions on high school athletes and how the injury can impact academic achievement. A concussion is an injury to the brain that results in loss of normal brain function and is usually temporary.

20 May 2010

New study shows CDPK1 controls toxoplasma's ability to secrete microneme proteins

Researchers at Washington University School of Medicine in St. Louis have identified a parasite protein that has all the makings of a microbial glass jaw: it's essential, it's vulnerable and humans have nothing like it, meaning scientists can take pharmacological swings at it with minimal fear of collateral damage.

20 May 2010

World Health Assembly news

Media outlets continue to track news emerging from the 63rd annual World Health Assembly (WHA) in Geneva.

20 May 2010

FDA grants 510(k) market clearance for EraGen's MultiCode-RTx HSV 1&2 Kit

EraGen Biosciences Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for EraGen's MultiCode®-RTx HSV 1&2 Kit.

20 May 2010

i3 completes acquisition of ChinaGate

i3, a global life sciences services company and subsidiary of Ingenix, has acquired ChinaGate, a contract research organization that provides product-development regulatory services for pharmaceutical, medical device and biotechnology companies looking to enter and access the Chinese market.

19 May 2010

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

TPP Global Development, an innovative drug development company, announced today it has raised £9.6m which will be used to execute the Company's strategy to develop early-stage pre-clinical drug candidates.

19 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus is a biotechnology company based on the scientific work of Dr. Michel Khrestchatisky and specializes in the development of peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS).

18 May 2010

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

The effects of multivitamins are most often researched in the elderly. This is one of very few studies to assess the relationship between supplementation with vitamins/minerals and psychological functioning in healthy groups of non-elderly adults. This study shows how a proprietary multivitamin and mineral supplement improves mood and mental performance while also reducing stress, mental tiredness and fatigue in healthy males.

14 May 2010

Central Nervous System News and Research

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

UCI study provides blueprint for enhanced treatment of inflammatory diseases

Mannitol improves effectiveness of HUCBs in neonatal rat models of cerebral palsy

Chakra Biotech Sdn Bhd announces name change to Cerca Insights Sdn Bhd

Adenosine plays major role in parlaying effects of acupuncture

Modified measles virus may hold potential for treatment of medulloblastoma

UCSF scientists discover new stem cell in developing human brain

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol

NeuroTherapeutics Pharma closes $43 million Series B financing round

AANS/CNS issue statement on Congress hearing of impact of concussions on high school athletes

New study shows CDPK1 controls toxoplasma's ability to secrete microneme proteins

World Health Assembly news

FDA grants 510(k) market clearance for EraGen's MultiCode-RTx HSV 1&2 Kit

i3 completes acquisition of ChinaGate

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

Event guide: The 7th CNS Drug Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News